Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-12-03T00:30:29.346Z Has data issue: false hasContentIssue false

P.096 A single institution experience with 217 average risk patients undergoing carotid angioplasty and stenting in the post CREST era, a real life experience

Published online by Cambridge University Press:  17 June 2016

B Drake
Affiliation:
(Toronto)
N Alizadeh Vakili
Affiliation:
(Toronto)
D Sarma
Affiliation:
(Toronto)
A Bharatha
Affiliation:
(Toronto)
T Marotta
Affiliation:
(Toronto)
W Montanera
Affiliation:
(Toronto)
A Chiu
Affiliation:
(Toronto)
J Spears
Affiliation:
(Toronto)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: The CREST trial remains the most influential study regarding choice of treatment modality for carotid revascularization in the modern era. The effect of the CREST trial on patient outcomes and changes to clinical practice are yet to be fully elucidated. Methods: We report a cohort of 217 consecutive symptomatic average risk patients undergoing CAS at St. Michael’s Hospital, between 2010 and 2016. Outcome measures were stroke, MI and death at 30 days post procedure. Of the 217 patients, 42 were above the age of 75 (19%). Results: The 30-day combined stroke, MI and death outcome for all patients was 4.1%. One death occurred (0.46%) in a patient who suffered an MI. One disabling stroke (0.46%) and 3 mild strokes (1.38%) with full recovery by 6 months occurred. Overall 4 patients suffered an MI (1.84%). Conclusions: As a result of the CREST trial in our single institutional experience there has been a clear migration to treating average risk patients using CAS, a treatment previously reserved for high risk patients. In this average risk cohort we report favourable outcomes when compared to the CREST trial as well as the firmly established benchmarks for CEA complications derived from the NASCET trial.

Type
Poster Presentations
Copyright
Copyright © The Canadian Journal of Neurological Sciences Inc. 2016